Ipamorelin vs Sermorelin
Two growth-hormone secretagogues that act on different receptors: Ipamorelin at the ghrelin receptor (GHS-R1a), Sermorelin at the GHRH receptor. A side-by-side research reference for laboratory study.
Overview
Ipamorelin and Sermorelin are both studied as growth-hormone (GH) secretagogues, meaning each is reported to promote GH release from the anterior pituitary in research models. The key distinction studied in the literature is the receptor each engages. Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Sermorelin is a 29-residue peptide corresponding to the biologically active 1-29 fragment of human growth hormone-releasing hormone (GHRH), and it acts at a separate receptor, the GHRH receptor (GHRH-R).
Because the two compounds engage distinct receptors and distinct intracellular pathways, they are frequently contrasted in research and are also examined in combined-pathway studies of how the two signalling routes interact. Ipamorelin was developed in the 1990s by Novo Nordisk (research code NNC 26-0161) and described as the first selective GH secretagogue (Raun et al., 1998). Sermorelin was the subject of clinical pharmacology decades earlier as a GHRH analogue and was approved by the US FDA in 1997 as a diagnostic and paediatric agent before the originator discontinued commercial production around 2008; it is discussed here strictly as a research reference compound.
Enhanced Research Compounds supplies both Ipamorelin and Sermorelin as lyophilised powders for in-vitro laboratory research only.
Molecular Profiles Compared
The two molecules differ markedly in size and class. Ipamorelin is a small five-residue peptide built on non-natural amino acids for stability and selectivity; Sermorelin is a much larger 29-residue peptide that reproduces the active N-terminal segment of native GHRH.
Ipamorelin
Sermorelin
Both compounds are supplied as lyophilised powder at ≥98% HPLC purity for laboratory research use.
Mechanism: Ipamorelin (GHS-R1a)
Findings below are drawn from published in-vitro and animal-model research:
- Ghrelin-receptor agonism: Ipamorelin binds and activates GHS-R1a, the receptor for endogenous ghrelin. In the foundational characterisation it released GH with potency and efficacy comparable to the earlier peptide GHRP-6 in pituitary cell and animal models (Raun et al., 1998).
- Calcium-dependent signalling: GHS-R1a is a Gq/11-coupled receptor; activation is reported to drive phospholipase C, inositol-trisphosphate generation, and intracellular calcium mobilisation in somatotrophs, a pathway distinct from the cAMP route used by GHRH (Casanueva et al., 2008).
- Selectivity profile:A defining feature reported for Ipamorelin is that, unlike some earlier GH secretagogues, it did not stimulate ACTH or cortisol release at levels different from GHRH in the characterisation studies, which is why it was described as the first “selective” GH secretagogue (Raun et al., 1998).
Mechanism: Sermorelin (GHRH-R)
- GHRH-receptor agonism: Sermorelin reproduces the 1-29 N-terminal fragment of GHRH, reported as the shortest segment retaining the full GH-releasing activity of the native hormone. It binds the GHRH receptor on pituitary somatotrophs (Walker, 2006).
- cAMP-dependent signalling: The GHRH receptor is Gs-coupled; receptor activation is described as raising intracellular cAMP in somatotrophs, a mechanism separate from the calcium-driven GHS-R1a pathway.
- Short circulating half-life: Sermorelin is reported to be cleared rapidly, with a circulating half-life on the order of 11-12 minutes in the pharmacology literature, in contrast to long-acting GHRH analogues engineered for extended duration.
- Upstream receptor target: Because Sermorelin acts upstream at the GHRH receptor, which sits within the somatostatin feedback loop described in GH-axis physiology, the literature treats GHRH-analogue research separately from research on GH itself (Walker, 2006).
Combined-Pathway Studies
Because Ipamorelin and Sermorelin engage two different receptors, they are often compared rather than treated as direct substitutes. A GHRH-receptor ligand and a ghrelin-receptor ligand signal through different second-messenger pathways (cAMP versus calcium), and published physiology research has examined how the two inputs interact (Bowers, 1998).
A notable mechanistic study reported that GHRH itself can interact with the ghrelin receptor GHS-R1a as a positive allosteric modulator, increasing the binding capacity of ghrelin rather than competing with it, which was proposed as one molecular basis for the interaction between the two receptor systems (Casanueva et al., 2008). For this reason a GHRH analogue alongside Ipamorelin is one of the most frequently examined combined-pathway designs. See Tesamorelin for another stabilised GHRH-analogue studied in this class.
Key Published Research
Ipamorelin, the first selective growth hormone secretagogue
Raun K, et al. European Journal of Endocrinology. 1998; 139(5):552-561 (PMID 9849822)
The foundational characterisation of Ipamorelin as a pentapeptide GHS-R1a agonist, reporting potent GH release in vitro and in vivo without the ACTH/cortisol stimulation seen with earlier secretagogues.
Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a
Casanueva FF, et al. Proceedings of the National Academy of Sciences USA. 2008; 105(51):20452-20457 (PMID 19088192)
Reports that GHRH binds GHS-R1a and acts as a positive allosteric modulator of ghrelin binding, a proposed molecular basis for interaction between the GHRH and ghrelin receptor systems.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF. Clinical Interventions in Aging. 2006; 1(4):307-308 (PMID 18046908)
Reviews Sermorelin as the GHRH(1-29) fragment acting at the GHRH receptor and discusses its short half-life and feedback-sensitive, GHRH-axis mechanism relative to direct GH.
Growth Hormone-Releasing Peptides
Bowers CY. Comprehensive Physiology (Handbook of Physiology). 1998
A review of the GH-releasing peptide class establishing that GHRP/ghrelin-type and GHRH-type inputs act through distinct receptors, and discussing how the two inputs interact.
Storage and Handling
Lyophilised (unreconstituted):Store at -20°C for long-term stability. Keep sealed and protected from light and moisture. Applies to both Ipamorelin and Sermorelin.
Reconstituted:Store at 2-8°C. Use within 30 days. Avoid repeated freeze-thaw cycles.
Recommended solvent: Bacteriostatic water or sterile water for laboratory use.
Frequently Asked Questions
What is the core difference between Ipamorelin and Sermorelin?
They act on different receptors. Ipamorelin is a ghrelin-mimetic that agonises GHS-R1a (the ghrelin receptor), while Sermorelin is a GHRH(1-29) analogue that agonises the GHRH receptor. In research models this corresponds to two distinct signalling pathways, calcium-dependent for GHS-R1a and cAMP-dependent for GHRH-R.
Why are they often compared?
Because they act at two different receptors through different pathways, and published research has examined how those receptor systems interact (Bowers, 1998; Casanueva et al., 2008). That is the basis for combined-pathway studies of a GHRH analogue alongside Ipamorelin.
How do their molecular profiles compare?
Ipamorelin is a small synthetic pentapeptide (C38H49N9O5, ~711.9 g/mol). Sermorelin is a much larger 29-residue peptide (C149H246N44O42S, ~3357.9 g/mol) reproducing the active N-terminal fragment of native GHRH.
What purity and form does ERC supply for research?
Both Ipamorelin and Sermorelin are supplied as lyophilised powder at ≥98% HPLC purity, intended strictly for in-vitro laboratory research only.
Disclaimer: This information is compiled from published peer-reviewed literature and is provided for educational and research reference purposes only. It does not constitute medical advice. Ipamorelin and Sermorelin sold by Enhanced Research Compounds are intended exclusively for in-vitro research and laboratory use. They are not therapeutic goods, are not listed on the ARTG, and are not approved for human or animal consumption.